B7-H3 Inhibitors in Oncology Clinical Trials: A Review
Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 53-66
DOI: 10.36401/jipo-23-18 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Kavanya Feustel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Early Phase Clinical Trials Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. There are clinical trials on the horizon that have not yet enrolled patients examining chimeric antigen receptor T-cell therapies, bi- and tri-specific killer engagers, and dual-affinity retargeting proteins. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Early Phase Clinical Trials Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
- Rocky Vista University Medical School, Greenwood Village, CO, USA.
ORCID-Profile: Kavanya Feustel
Zitieren
APA
Feustel, K., Martin, J., & Falchook, G. S. (2024). B7-H3 Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 7(1), 53-66. https://doi.org/10.36401/jipo-23-18
Vancouver
Feustel K, Martin J, Falchook GS. B7-H3 Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2024;7(1):53-66. doi:10.36401/jipo-23-18
BibTeX
@article{Feustel2024,
author = {Feustel, Kavanya and Martin, Jared and Falchook, Gerald S},
title = {B7-H3 Inhibitors in Oncology Clinical Trials: A Review},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2024},
volume = {7},
number = {1},
pages = {53--66},
doi = {10.36401/jipo-23-18}
}
EUVIMED